Every material Form 8-K Haemonetics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Haemonetics reported second-quarter fiscal 2026 revenue of $327.3 million, down 5.3% from a year earlier, while GAAP net income rose 14.3% and adjusted earnings per diluted share rose 13.4% to $1.27. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.80 to $5.00 and its free cash flow guidance to $170 million to $210 million, and reaffirmed its adjusted operating margin guidance of 26% to 27%.
Q2 revenue was $327.3 million, down 5.3%; organic ex-CSL revenue grew 9.4%.
GAAP earnings per diluted share were $0.81, up from $0.66; adjusted earnings per diluted share were $1.27.
Fiscal 2026 adjusted EPS guidance raised to $4.80 to $5.00 from $4.70 to $5.00; free cash flow guidance raised to $170 million to $210 million from $160 million to $200 million.
Q2 operating expenses included $8.6 million of intangible asset impairment charges.
Haemonetics reported first-quarter fiscal 2026 revenue of $321.4 million, down 4.4% from a year earlier, and GAAP earnings of $0.70 per diluted share compared with $0.74 a year earlier. Adjusted earnings per diluted share rose 7.8% to $1.10, and the company reaffirmed its fiscal 2026 guidance, including adjusted earnings per diluted share of $4.70 to $5.00. For shareholders, the quarter shows lower reported revenue and GAAP profit alongside higher adjusted profit and an unchanged outlook.
Revenue was $321.4 million, down 4.4%; organic revenue rose 0.5% and organic ex-CSL revenue rose 12.9%
GAAP earnings per diluted share were $0.70 versus $0.74; adjusted earnings per diluted share were $1.10, up 7.8%
Adjusted gross margin was 60.8%, up 550 basis points; free cash flow was $2.5 million
Fiscal 2026 guidance reaffirmed: adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
Haemonetics reported fourth-quarter fiscal 2025 revenue of $330.6 million, down 3.7% from a year earlier, while GAAP earnings per diluted share rose to $1.17 from $0.40 and adjusted EPS rose 37.8% to $1.24. The company also issued fiscal 2026 guidance, including adjusted EPS of $4.70 to $5.00, and approved a market and regional alignment initiative expected to bring about $20 million in restructuring charges and about $30 million in annualized savings.
Q4 fiscal 2025 revenue $330.6 million, down 3.7%; organic revenue down 0.2%, with Plasma down 9.1% and Blood Center down 22.2%
Q4 GAAP EPS $1.17 vs $0.40; adjusted EPS $1.24, up 37.8%
Fiscal 2026 guidance: adjusted EPS $4.70 to $5.00, adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
Alignment initiative: about $20 million in charges, mostly cash, through fiscal 2027; about $30 million annualized savings once complete
Haemonetics appointed Frank W. Chan, Ph.D., former President of Medtronic's Acute Care & Monitoring business, as Executive Vice President and Chief Operating Officer, effective April 7, 2025, and promoted Roy Galvin to Executive Vice President and Chief Commercial Officer effective immediately. The filing describes these as leadership changes in the executive team; it reports no financial results or guidance, so it does not change reported figures.
Frank W. Chan, Ph.D., 55, starts as COO on April 7, 2025, overseeing R&D, regulatory, global manufacturing and supply chain, and reporting to CEO Christopher A. Simon
Chan's pay includes a $550,000 base salary, a target bonus of 80% of base salary, and a long-term equity award target value of $1,600,000, subject to Compensation Committee approval
Chan receives a $350,000 sign-on bonus, with $300,000 repayable in the first 12 months and $150,000 repayable between months 12 and 24 if he leaves voluntarily or is terminated for cause
Roy Galvin's expanded CCO role covers Global Hospital, Global Plasma and Blood Center; Stewart Strong, President, Global Hospital, stays in his role through April 1, 2025, then advises the CEO temporarily
Haemonetics reported third-quarter fiscal 2025 revenue of $348.5 million, up 3.7%, and GAAP earnings of $0.74 per diluted share, up from $0.61. The company lowered its fiscal 2025 reported revenue growth guidance to 3% to 5% from 5% to 8% and cut free cash flow guidance to $120 million to $140 million from $130 million to $180 million, while narrowing its adjusted earnings per share guidance to $4.50 to $4.70.
Third-quarter revenue was $348.5 million, up 3.7%, while organic revenue decreased 0.3%.
GAAP earnings per diluted share were $0.74, versus $0.61 a year earlier; adjusted earnings per diluted share were $1.19, up 14.4%.
Fiscal 2025 reported revenue growth guidance was lowered to 3% to 5% from 5% to 8%.
Free cash flow guidance was cut to $120 million to $140 million from $130 million to $180 million; adjusted earnings per share guidance was narrowed to $4.50 to $4.70 from $4.45 to $4.75.
Haemonetics said Executive Vice President of Global Manufacturing and Supply Chain Josep Llorens will retire effective July 11, 2025. He will stay in his role while the company searches for a successor and will help the CEO with the transition until he leaves. The change involves a named executive officer in charge of manufacturing and supply chain, but the filing gives no financial impact.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, will retire effective July 11, 2025
Llorens will remain in his current role while the company searches for a successor
Llorens will assist CEO Christopher A. Simon with the transition until his retirement
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Haemonetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →